🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

DocGo extends Bayhealth transport services contract

Published 10/09/2024, 07:42 PM
DCGO
-

NEW YORK - DocGo Inc. (NASDAQ: DCGO), a prominent provider of mobile health services, has announced the renewal of its subsidiary Ambulnz's contract with Bayhealth, Delaware's largest healthcare system. The three-year contract extension reflects Ambulnz's reliable non-emergency transportation services, with over 20,000 trips expected to be completed within the contract's duration.

Since January 2022, Ambulnz has been instrumental in assisting Bayhealth with managing patient flow by providing non-emergency transportation, which has helped ensure patients receive timely care. Bayhealth's Vice President of Patient Care Services, Christine Keithly, acknowledged the value of Ambulnz's services in streamlining patient flow and improving care coordination.

In July 2024, DocGo expanded its services in Delaware by launching emergency medical and 911 services in Dover (NYSE:DOV). Over the past two years, the company has made significant investments in the region, including purchasing new ambulances and advanced EMS equipment, as well as tripling its workforce in Delaware. This strategic growth demonstrates the strong partnership between DocGo, Bayhealth, and the city of Dover, aiming to address both emergency and non-emergency medical needs, enhance patient outcomes, and support the local healthcare infrastructure.

DocGo operates with a mission to revolutionize proactive healthcare by providing accessible care outside of traditional healthcare settings. Its integrated technology platform offers mobile health services, remote patient monitoring, and ambulance services, aiming to improve patient care quality and drive business efficiencies for healthcare facilities and insurers.

The information in this article is based on a press release statement from DocGo Inc.

In other recent news, DocGo Inc. announced robust financial growth in its Q2 2024 earnings report, with a notable revenue of $164.9 million and an adjusted EBITDA of $17.2 million. The company anticipates a cash flow from operations between $80 million and $90 million for the year. DocGo also recently welcomed Stephen K. Klasko, M.D., M.B.A as its new independent, non-executive Chair of the Board of Directors. Klasko's experience in healthcare and higher education leadership is expected to bolster DocGo's mobile health initiatives and value-based care strategies.

In addition, DocGo has appointed Eiwe Lingefors as its new Chief Information Officer, tasked with overseeing the company's cybersecurity efforts. In a bid to diversify its revenue streams, DocGo is expanding its market presence, securing several new contracts, and establishing a Medical Advisory Board to enhance its clinical programs and research. For 2024, the company reaffirmed its guidance of $600 million to $650 million in revenue and $65 million to $75 million in adjusted EBITDA. These recent developments underscore DocGo's commitment to maintaining strong growth and diversifying its customer base.

InvestingPro Insights

DocGo's contract renewal with Bayhealth aligns well with the company's strong financial performance and growth trajectory. According to InvestingPro data, DocGo has demonstrated impressive revenue growth, with a 64.49% increase in the last twelve months as of Q2 2024. This growth is further reflected in the company's quarterly revenue growth of 31.45% in Q2 2024, indicating sustained momentum in its business operations.

The company's focus on expanding its services in Delaware, including the launch of emergency medical and 911 services in Dover, appears to be part of a successful growth strategy. This is supported by an InvestingPro Tip which notes that DocGo's net income is expected to grow this year. Additionally, the company's profitability over the last twelve months suggests that its expansion efforts are translating into financial success.

Another relevant InvestingPro Tip indicates that DocGo is trading at a low revenue valuation multiple. This could be of interest to investors considering the company's strong growth and recent contract renewal. With a P/E ratio of 10.82, DocGo may represent an attractive investment opportunity in the healthcare services sector.

For readers interested in a more comprehensive analysis, InvestingPro offers 5 additional tips for DocGo, providing deeper insights into the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.